Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | MMP1 | P03956 | 4/20 | 0.46 |
| ▸ | MMP2 | P08253 | 4/20 | 0.46 |
| ▸ | MMP9 | P14780 | 4/20 | 0.46 |
| ▸ | MMP8 | P22894 | 4/20 | 0.46 |
| ▸ | MMP13 | P45452 | 4/20 | 0.46 |
| ▸ | F2 | P00734 | 4/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL474710 | 0.96 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| Perflenapent SCHEMBL14763328 | 0.96 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL9505503 | 0.96 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| Perflexane SCHEMBL3192336 | 0.96 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| Perflutren SCHEMBL1470237 | 0.92 | CA2 (0.41) | CA2CA1MMP1MMP2MMP9 | |
| Perflubutane SCHEMBL6557063 | 0.85 | TSHR (0.57) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL6898759 | 0.84 | CA2 (0.50) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1469649 | 0.82 | CA2 (0.40) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL11563004 | 0.82 | TSHR (0.53) | CA2CA1MMP1MMP2MMP9 | |
| Perflubutane SCHEMBL4458683 | 0.80 | CA2 (0.50) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852101-A | Sulfonyloxy high-valence iodized salt and preparation method thereof | 中国人民解放军军事科学院防化研究院 | 2024-10-29 | — | — | CN | claimed |
| WO-2024064745-A1 | SYNTHESIS OF RELDESEMTIV | CYTOKINETICS, INCORPORATED (US) | 2024-03-28 | — | — | WO | claimed |
| CN-117619175-A | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2024-03-01 | — | — | CN | claimed |
| CN-116675861-A | Preparation method of modified polyethersulfone/polyetherimide polymer alloy | 深圳先进技术研究院 | 2023-09-01 | — | — | CN | claimed |
| CN-116457335-A | Process for preparing 3-fluoro-5- (((1S, 2 aR) -1,3, 4-pentafluoro-2 a-hydroxy-2, 2a,3, 4-tetrahydro-1H-cyclopenta [ cd ] inden-7-yl) oxy) benzonitrile and polymorphs thereof | 尼坎治疗公司 | 2023-07-18 | — | — | CN | claimed |
| US-10794853-B2 | Methods for depositing polymer layer for sensor applications via hot wire chemical vapor deposition | APPLIED MATERIALS, INC. (US) | 2020-10-06 | — | — | US | claimed |
| EP-3551780-A1 | METHODS FOR DEPOSITING POLYMER LAYER FOR SENSOR APPLICATIONS VIA HOT WIRE CHEMICAL VAPOR DEPOSITION | Applied Materials, Inc. (US) | 2019-10-16 | — | — | EP | claimed |
| US-20180164245-A1 | METHODS FOR DEPOSITING POLYMER LAYER FOR SENSOR APPLICATIONS VIA HOT WIRE CHEMICAL VAPOR DEPOSITION | APPLIED MATERIALS, INC. | 2018-06-14 | — | — | US | claimed |
| US-8906454-B2 | Methods for depositing metal-polymer composite materials atop a substrate | APPLIED MATERIALS, INC. (US) | 2014-12-09 | — | — | US | claimed |
| WO-2013039862-A2 | METHODS FOR DEPOSITING METAL-POLYMER COMPOSITE MATERIALS ATOP A SUBSTRATE | APPLIED MATERIALS, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| US-20130065401-A1 | METHODS FOR DEPOSITING METAL-POLYMER COMPOSITE MATERIALS ATOP A SUBSTRATE | APPLIED MATERIALS, INC. (US) | 2013-03-14 | — | — | US | claimed |
| US-8324417-B2 | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof | VIROBAY, INC. (US) | 2012-12-04 | — | — | US | claimed |
| WO-2011022429-A2 | PROCESS FOR THE PREPARATION OF (S)-2-AMINO-5-CYCLOPROPYL-4,4-DIFLUOROPENTANOIC ACID AND ALKYL ESTERS AND ACID SALTS THEREOF | VIROBAY, INC. (US) | 2011-02-24 | — | — | WO | claimed |
| US-20110046406-A1 | PROCESS FOR THE PREPARATION OF (S)-2-AMINO-5-CYCLOPROPYL-4,4-DIFLUOROPENTANOIC ACID AND ALKYL ESTERS AND ACID SALTS THEREOF | VIROBAY, INC. (US) | 2011-02-24 | — | — | US | claimed |
| US-7429628-B2 | Method of making a thermoplastic composition containing an antistatic agent | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-09-30 | — | — | US | claimed |
| US-20080081857-A1 | METHOD OF MAKING A THERMOPLASTIC COMPOSITION CONTAINING AN ANTISTATIC AGENT | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2008-04-03 | — | — | US | claimed |
| US-6566542-B2 | Such as 17-alpha-fluoro-11-beta-(4-(2-(1-piperidinyl) ethoxy) phenyl)-estra-1,3,5(10)-trien-3-ol for treatment of osteoporosis and cardiovascular protection; side effect reduction; provides alternative to estradiol | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | claimed |
| EP-1090027-B1 | NOVEL 17-HALOGENATED 19-NOR STEROIDS, METHOD AND INTERMEDIATES FOR PREPARING SAME, USE AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA SA (FR) | 2003-04-16 | — | — | EP | claimed |
| US-20030022874-A1 | New 17-halogenated 19-nor steroids, preparation process and intermediates, use as medicaments and the pharmaceutical compositions containing them | BOUALI YASMINA (FR) | 2003-01-30 | — | — | US | claimed |
| EP-4665332-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2025-12-24 | — | — | EP | disclosed |
| CN-120072800-A | Microelectronic assembly with through-glass via stress relief in glass core | 英特尔公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-119585258-A | Novel 7-substituted indole sulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-113228335-B | Organic light emitting device | 株式会社LG化学 | 2024-11-29 | — | — | CN | disclosed |
| CN-118852101-A | Sulfonyloxy high-valence iodized salt and preparation method thereof | 中国人民解放军军事科学院防化研究院 | 2024-10-29 | — | — | CN | disclosed |
| CN-112868111-B | Organic light emitting device | 株式会社LG化学 | 2024-09-06 | — | — | CN | disclosed |
| WO-2024173412-A2 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-118510783-A | Spiro modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2024-08-16 | — | — | CN | disclosed |
| CN-113228331-B | Organic light emitting device | 株式会社LG化学 | 2024-08-02 | — | — | CN | disclosed |
| CN-118201642-A | Linker for antibody drug conjugates | 奥隆制药 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024064745-A1 | SYNTHESIS OF RELDESEMTIV | CYTOKINETICS, INCORPORATED (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-113646915-B | Organic light emitting device | 株式会社LG化学 | 2024-03-19 | — | — | CN | disclosed |
| CN-117619175-A | Nanofiltration membrane and preparation method and application thereof | 清华大学 | 2024-03-01 | — | — | CN | disclosed |
| CN-112469719-B | Heterocondensed pyridone compounds and their use as IDH inhibitors | 内尔维亚诺医疗科学公司 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023242598-A1 | BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2023-12-21 | — | — | WO | disclosed |
| CN-117098762-A | Process for preparing bicyclic ketone compounds | 基因泰克公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-111936506-B | Compound and organic light-emitting element comprising same | 株式会社LG化学 | 2023-11-07 | — | — | CN | disclosed |
| CN-116940354-A | Fused heteroaryl compounds and their use as CaMKII inhibitors | 卡都瑞恩医药股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-113924665-B | Organic light emitting device | 株式会社LG化学 | 2023-09-29 | — | — | CN | disclosed |
| CN-116675861-A | Preparation method of modified polyethersulfone/polyetherimide polymer alloy | 深圳先进技术研究院 | 2023-09-01 | — | — | CN | disclosed |
| CN-116457335-A | Process for preparing 3-fluoro-5- (((1S, 2 aR) -1,3, 4-pentafluoro-2 a-hydroxy-2, 2a,3, 4-tetrahydro-1H-cyclopenta [ cd ] inden-7-yl) oxy) benzonitrile and polymorphs thereof | 尼坎治疗公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-111655697-B | Compound and organic light-emitting diode comprising same | 株式会社LG化学 | 2023-05-19 | — | — | CN | disclosed |
| CN-111479857-B | Multilayer composite material comprising a specific polycarbonate composition as matrix material | 科思创德国股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-111465635-B | Multilayer composite material comprising a specific polycarbonate composition as matrix material | 科思创德国股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20220145037-A1 | METHODS OF PREPARATION OF OMNIPHOBIC SURFACES | NUTECH VENTURES (US) | 2022-05-12 | — | — | US | disclosed |
| US-11312688-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-26 | — | — | US | disclosed |
| CN-109851531-B | Preparation method of (N-methyl perfluoroalkyl sulfonamide) ethyl acrylate | 武汉松石科技股份有限公司 | 2021-06-08 | — | — | CN | disclosed |
| WO-2021030670-A1 | ARTICLE INCLUDING ELASTOMERIC CORE AND VAPOR DEPOSITED FLUOROELASTOMERIC COATING | QUADION LLC (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-3638654-B1 | MELT ADDITIVE COMPOUNDS, METHODS OF USING THE SAME, AND ARTICLES AND COMPOSITIONS INCLUDING THE SAME | 3M INNOVATIVE PROPERTIES CO (US) | 2021-01-27 | — | — | EP | disclosed |
| CN-112028902-A | Novel heterocyclic compound and organic light-emitting element using same | 株式会社LG化学 | 2020-12-04 | — | — | CN | disclosed |
| US-10794853-B2 | Methods for depositing polymer layer for sensor applications via hot wire chemical vapor deposition | APPLIED MATERIALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200308119-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2020-10-01 | — | — | US | disclosed |
| US-10723703-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-07-28 | — | — | US | disclosed |
| CN-111349103-A | Heterocyclic compound and organic light-emitting element using same | 株式会社LG化学 | 2020-06-30 | — | — | CN | disclosed |
| EP-3551780-A1 | METHODS FOR DEPOSITING POLYMER LAYER FOR SENSOR APPLICATIONS VIA HOT WIRE CHEMICAL VAPOR DEPOSITION | Applied Materials, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190218203-A1 | Neuroprotective Compounds and Use Thereof | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2019-07-18 | — | — | US | disclosed |
| US-20190084938-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2019-03-21 | — | — | US | disclosed |
| US-10183913-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-01-22 | — | — | US | disclosed |
| EP-3050872-B1 | Fluorinated sulfonamide as electrolyte (co-)solvent for lithium-ion batteries | UNIV MUENSTER WESTFAELISCHE WILHELMS (DE) | 2018-10-03 | — | — | EP | disclosed |
| US-10087146-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-10-02 | — | — | US | disclosed |
| US-20180273489-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2018-09-27 | — | — | US | disclosed |
| US-20180164245-A1 | METHODS FOR DEPOSITING POLYMER LAYER FOR SENSOR APPLICATIONS VIA HOT WIRE CHEMICAL VAPOR DEPOSITION | APPLIED MATERIALS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-9976165-B2 | Methods for increasing molecular diversity of polyketides and non-ribosomal proteins | ISOMERASE THERAPEUTICS, LTD. (GB) | 2018-05-22 | — | — | US | disclosed |
| US-9902713-B2 | Neuroprotective compounds and use thereof | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-27 | — | — | US | disclosed |
| US-9828722-B2 | Blends of fluoroalkyl-containing ester oligomers with polycarbodiimide(s) | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2017189215-A1 | ARTICLES SUBJECT TO ICE FORMATION COMPRISING A REPELLENT SURFACE COMPRISING A FLUOROCHEMICAL MATERIAL | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-11-02 | — | — | WO | disclosed |
| US-20170217902-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2017-08-03 | — | — | US | disclosed |
| US-9663472-B2 | Pyrazole compound | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20170101659-A1 | METHODS FOR INCREASING MOLECULAR DIVERSITY OF POLYKETIDES AND NON-RIBOSOMAL PROTEINS | Isomerase Therapeutics Ltd. (GB) | 2017-04-13 | — | — | US | disclosed |
| WO-2017016943-A1 | METHOD FOR RECOVERING SULFONIC ESTERS OR SULFONYL HALIDES FROM SALTS OF SULFONIC ACIDS | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2017-02-02 | — | — | WO | disclosed |
| US-9505773-B2 | Rapamycin analogues and their pharmaceutical use | Isomerase Therapeutics Ltd. (GB) | 2016-11-29 | — | — | US | disclosed |
| US-20160272619-A1 | Neuroprotective Compounds and Use Thereof | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3068388-A2 | NEUROPROTECTIVE COMPOUNDS AND USE THEREOF | Board of Regents of the University of Texas System (US) | 2016-09-21 | — | — | EP | disclosed |
| EP-3050872-A1 | Fluorinated sulfonamide as electrolyte (co-)solvent for lithium-ion batteries | Westfälische Wilhelms-Universität Münster (DE) | 2016-08-03 | — | — | EP | disclosed |
| US-20160176893-A1 | RAPAMYCIN ANALOGUES AND THEIR PHARMACEUTICAL USE | ISOMERASE THERAPEUTICS, LTD. (GB) | 2016-06-23 | — | — | US | disclosed |
| EP-2594559-B1 | PYRAZOLE COMPOUND | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-02-24 | — | — | EP | disclosed |
| EP-2417184-B1 | PROCESS FOR THE MANUFACTURE OF FUNCTIONAL PFPE DERIVATIVE | SOLVAY SPECIALTY POLYMERS IT (IT) | 2016-01-06 | — | — | EP | disclosed |
| WO-2015070234-A9 | NEUROPROTECTIVE COMPOUNDS AND USE THEREOF | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-12-10 | — | — | WO | disclosed |
| EP-2091926-B1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| EP-2638116-B1 | OPTICAL DEVICE SURFACE TREATMENT PROCESS AND SMUDGE-RESISTANT ARTICLE PRODUCED THEREBY | 3M INNOVATIVE PROPERTIES CO (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8993116-B2 | Blends of fluoroalkyl-containing ester oligomers with polydicarbodiimide(S) | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8975445-B2 | Process for the manufacture of functional PFPE derivative | SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) | 2015-03-10 | — | — | US | disclosed |
| US-8906454-B2 | Methods for depositing metal-polymer composite materials atop a substrate | APPLIED MATERIALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140315971-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2014-10-23 | — | — | US | disclosed |
| US-8809383-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-14 | — | — | US | disclosed |
| US-8735599-B2 | Substituted imidazole derivates | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140031406-A1 | PYRAZOLE COMPOUND | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8569353-B2 | Pyrazole compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2638116-A1 | OPTICAL DEVICE SURFACE TREATMENT PROCESS AND SMUDGE-RESISTANT ARTICLE PRODUCED THEREBY | 3M Innovative Properties Company (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2396431-B1 | LEATHER ARTICLE HAVING IMPROVED SOIL RESISTANCE AND METHOD OF MAKING SAME | 3M INNOVATIVE PROPERTIES CO (US) | 2013-09-11 | — | — | EP | disclosed |
| US-20130229378-A1 | OPTICAL DEVICE SURFACE TREATMENT PROCESS AND SMUDGE-RESISTANT ARTICLE PRODUCED THEREBY | 3M INNOVATIVE PROPERTIES COMPANY | 2013-09-05 | — | — | US | disclosed |
| EP-2594559-A1 | PYRAZOLE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116296-A1 | PYRAZOLE COMPOUND | NEUROINNOVATECH APS (DK) | 2013-05-09 | — | — | US | disclosed |
| WO-2013039862-A2 | METHODS FOR DEPOSITING METAL-POLYMER COMPOSITE MATERIALS ATOP A SUBSTRATE | APPLIED MATERIALS, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065401-A1 | METHODS FOR DEPOSITING METAL-POLYMER COMPOSITE MATERIALS ATOP A SUBSTRATE | APPLIED MATERIALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| EP-1765789-B1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | CHIRON CORPORATION | 2013-01-17 | — | — | US | disclosed |
| US-8324417-B2 | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof | VIROBAY, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8318791-B2 | Substituted imidazole derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2012105586-A1 | PERFLUOROBUTANE SULFONYL FLUORIDE, POTASSIUM PERFLUOROBUTANE SULFONATE SALT, AND METHOD FOR PRODUCING PERFLUOROBUTANE SULFONYL FLUORIDE | 三菱マテリアル株式会社 (JP) | 2012-08-09 | — | — | WO | disclosed |
| EP-1743014-B1 | FLUORINATED SULFONAMIDE SURFACTANTS FOR AQUEOUS CLEANING SOLUTIONS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2012064649-A1 | OPTICAL DEVICE SURFACE TREATMENT PROCESS AND SMUDGE-RESISTANT ARTICLE PRODUCED THEREBY | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-18 | — | — | WO | disclosed |
| US-8129358-B2 | Substituted pyrazole and triazole compounds as KSP inhibitors | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2417184-A1 | PROCESS FOR THE MANUFACTURE OF FUNCTIONAL PFPE DERIVATIVE | Solvay Solexis S.p.A. (IT) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028858-A1 | Process for the manufacture of functional PFPE derivative | SOLVAY SOLEXIS S.P.A. (IT) | 2012-02-02 | — | — | US | disclosed |
| EP-1912972-B1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2011-09-28 | — | — | EP | disclosed |
| EP-1832574-B1 | Methods of making an antistatic agent | SABIC INNOVATIVE PLASTICS IP (NL) | 2011-08-10 | — | — | EP | disclosed |
| US-7985723-B2 | Fluorinated sulfonamide surfactants for aqueous cleaning solutions | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | PIRAMAL IMAGING SA (CH) | 2011-03-17 | — | — | US | disclosed |
| US-7902240-B2 | Kinesin spindle protein (KSP); anticancer agents; antiproliferative agents; e.g. N-((S)-3-amino-4-fluorobutyl)-N ((R)-1-(1-benzyl-3-(2,5-difluorophenyl)-1H-1,2,4-triazol-5-yl)-2,2-dimethylpropyl)nicotinamide | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| WO-2011022429-A2 | PROCESS FOR THE PREPARATION OF (S)-2-AMINO-5-CYCLOPROPYL-4,4-DIFLUOROPENTANOIC ACID AND ALKYL ESTERS AND ACID SALTS THEREOF | VIROBAY, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20110046406-A1 | PROCESS FOR THE PREPARATION OF (S)-2-AMINO-5-CYCLOPROPYL-4,4-DIFLUOROPENTANOIC ACID AND ALKYL ESTERS AND ACID SALTS THEREOF | VIROBAY, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2282981-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-20100320416-A1 | FLUORINATED SULFONAMIDE SURFACTANTS FOR AQUEOUS CLEANING SOLUTIONS | 3M INNOVATIVE PROPERTIES COMPANY | 2010-12-23 | — | — | US | disclosed |
| US-20100278751-A1 | RADIOLABELED 2-AMINO-4-ALKYL-6-(HALOALKYL)PYRIDINE COMPOUNDS AND THEIR USE IN DIAGNOSTIC IMAGING | WASHINGTON UNIVERSITY (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2010115855-A1 | PROCESS FOR THE MANUFACTURE OF FUNCTIONAL PFPE DERIVATIVE | SOLVAY SOLEXIS S.P.A. (IT) | 2010-10-14 | — | — | WO | disclosed |
| US-7811978-B2 | Fluorinated sulfonamide surfactants for aqueous cleaning solutions | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20100227148-A1 | WATER- AND OIL-REPELLENCY IMPARTING ESTER OLIGOMERS COMPRISING PERFLUOROALKYL MOIETIES | 3M INNOVATIVE PROPERTIES COMPANY | 2010-09-09 | — | — | US | disclosed |
| EP-1737814-B1 | METHODS OF MAKING AN ANTISTATIC AGENT | SABIC INNOVATIVE PLASTICS IP (NL) | 2010-06-09 | — | — | EP | disclosed |
| EP-2167462-A2 | WATER- AND OIL-REPELLENCY IMPARTING ESTER OLIGOMERS COMPRISING PERFLUOROALKYL MOIETIES | 3M Innovative Properties Company (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009141090-A9 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-25 | — | — | WO | disclosed |
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| US-7626040-B2 | Substituted imidazole compounds as KSP inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2009141090-A1 | {F-19} -LABELED L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | WO | disclosed |
| US-20090258016-A1 | Substituted imidazole derivatives | WANG WEIBO | 2009-10-15 | — | — | US | disclosed |
| EP-2091926-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | Novartis AG (CH) | 2009-08-26 | — | — | EP | disclosed |
| US-7576221-B2 | N-(3-aminopropyl)-N-[(1R)-1-(1-benzyl-4-phenyl-1H-imidazol-2-yl)-2-methylpropyl]-4-methylbenzamide; kinesin-related proteins (KRP) inhibitors; anticarcinogenic agent | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| WO-2008154414-A2 | WATER- AND OIL-REPELLENCY IMPARTING ESTER OLIGOMERS COMPRISING PERFLUOROALKYL MOIETIES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306238-A1 | WATER- AND OIL-REPELLENCY IMPARTING ESTER OLIGOMERS COMPRISING PERFLUOROALKYL MOIETIES | 3M INNOVATIVE PROPERTIES COMPANY | 2008-12-11 | — | — | US | disclosed |
| US-7449572-B2 | Process and intermediates for preparing 17-halogenated 19-norsteroid compounds | AVENTIS PHARMA S.A. (FR) | 2008-11-11 | — | — | US | disclosed |
| US-20080269526-A1 | METHODS OF MAKING AN ANTISTATIC AGENT | SAIC INNOVATIVE PLASTICS, IP B.V. (NL) | 2008-10-30 | — | — | US | disclosed |
| WO-2008122611-A1 | PROCESS FOR THE MANUFACTURE OF FLUORINATED COMPOUNDS | Solvay (Société Anonyme) (BE) | 2008-10-16 | — | — | WO | disclosed |
| US-7429628-B2 | Method of making a thermoplastic composition containing an antistatic agent | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2008-09-30 | — | — | US | disclosed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | disclosed |
| WO-2008063912-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| EP-1912972-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | Novartis AG (CH) | 2008-04-23 | — | — | EP | disclosed |
| US-20080081857-A1 | METHOD OF MAKING A THERMOPLASTIC COMPOSITION CONTAINING AN ANTISTATIC AGENT | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2008-04-03 | — | — | US | disclosed |
| US-20080078747-A1 | FLUORINATED SULFONAMIDE SURFACTANTS FOR AQUEOUS CLEANING SOLUTIONS | 3M INNOVATIVE PROPERTIES COMPANY | 2008-04-03 | — | — | US | disclosed |
| US-20080015377-A1 | METHODS OF MAKING AN ANTISTATIC AGENT | GENERAL ELECTRIC COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| US-7309735-B2 | One-step, phosphonium haloalkylsulfonate antistatic agent by combining an alkyl sulfonate salt of lithium or Sodium with a tetraalkylphosphonium halogen in an aqueous medium; simple mixing of the reactants results in a precipitation of the anti-static molecule in high yield | GENERAL ELECTRIC COMPANY (US) | 2007-12-18 | — | — | US | disclosed |
| US-7294610-B2 | Fluorinated sulfonamide surfactants for aqueous cleaning solutions | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| EP-1832574-A2 | Methods of making an antistatic agent | General Electric Company (US) | 2007-09-12 | — | — | EP | disclosed |
| EP-1812502-A2 | METHODS OF MAKING AN ANTISTATIC AGENT | General Electric Company (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070129472-A1 | METHOD OF MAKING A THERMOPLASTIC COMPOSITION CONTAINING AN ANTISTATIC AGENT | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2007-06-07 | — | — | US | disclosed |
| US-7211690-B2 | Methods of making an antistatic agent | GENERAL ELECTRIC COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1765789-A1 | N-(1-(1-BENZYL-4-PHENYL-1H-IMIDAZOL-2-YL)-2,2-DIMETHYLPROPYL)BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007021794-A1 | SUBSTITUTED IMIDAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | disclosed |
| EP-1743014-A1 | FLUORINATED SULFONAMIDE SURFACTANTS FOR AQUEOUS CLEANING SOLUTIONS | 3M Innovative Properties Company (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1737814-A2 | METHODS OF MAKING AN ANTISTATIC AGENT | GENERAL ELECTRIC COMPANY (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006052522-A2 | METHODS OF MAKING AN ANTISTATIC AGENT | GENERAL ELECTRIC COMPANY (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100327-A1 | Methods of making an antistatic agent | CITIBANK, N.A., AS COLLATERAL AGENT | 2006-05-11 | — | — | US | disclosed |
| US-20060009472-A1 | Substituted imidazole derivatives | CHIRON CORPORATION | 2006-01-12 | — | — | US | disclosed |
| WO-2006002236-A1 | N- (1- (1-BENZYL -4-PHENYL-1H-IMIDAZOL-2-YL) -2,2-DYMETHYLPROPYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS KINESIN SPINDLE PROTEIN (KSP) INHIBITORS FOR THE TREATMENT OF CANCER | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005100307-A2 | METHODS OF MAKING AN ANTISTATIC AGENT | GENERAL ELECTRIC COMPANY (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050228194-A1 | Methods of making an antistatic agent | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2005-10-13 | — | — | US | disclosed |
| WO-2005095567-A1 | FLUORINATED SULFONAMIDE SURFACTANTS FOR AQUEOUS CLEANING SOLUTIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050197273-A1 | Fluorinated sulfonamide surfactants for aqueous cleaning solutions | 3M INNOVATIVE PROPERTIES COMPANY | 2005-09-08 | — | — | US | disclosed |
| US-20040224933-A1 | Novel process and intermediates for preparing 17-halogenated 19-norsteroid compounds | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
| EP-1131270-B1 | PROCESS FOR CONVERTING AN ALCOHOL TO THE CORRESPONDING FLUORIDE | 3M INNOVATIVE PROPERTIES CO (US) | 2004-04-07 | — | — | EP | disclosed |
| US-6566542-B2 | Such as 17-alpha-fluoro-11-beta-(4-(2-(1-piperidinyl) ethoxy) phenyl)-estra-1,3,5(10)-trien-3-ol for treatment of osteoporosis and cardiovascular protection; side effect reduction; provides alternative to estradiol | AVENTIS PHARMA S.A. (FR) | 2003-05-20 | — | — | US | disclosed |
| US-20030031844-A1 | Layer of perfluoroalkyl sulfonic ammonium acid salts, phosphonium acid salts and sulfonium acid salts and polycarbonate (co)polymers | BAYER AKTIENGESELLSCHAFT (DE) | 2003-02-13 | — | — | US | disclosed |
| US-20030022874-A1 | New 17-halogenated 19-nor steroids, preparation process and intermediates, use as medicaments and the pharmaceutical compositions containing them | BOUALI YASMINA (FR) | 2003-01-30 | — | — | US | disclosed |
| US-6423700-B1 | 17-halogenated 19-nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same | AVENTIS PHARMA S.A. (FR) | 2002-07-23 | — | — | US | disclosed |
| US-6365068-B1 | IN SOLVENT | HYDRO-QUEBEC (CA) | 2002-04-02 | — | — | US | disclosed |
| EP-1131270-A1 | PROCESS FOR CONVERTING AN ALCOHOL TO THE CORRESPONDING FLUORIDE | 3M Innovative Properties Company (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6248889-B1 | FORMING MIXTURE COMPRISING AT LEAST ONE FLUORINATED, SATURATED ALIPHATIC OR ALICYCLIC SULFONYL FLUORIDE AND AT LEAST ONE PRIMARY OR SECONDARY ALCOHOL, ADDING MOLAR EXCESS OF STRONG, APROTIC, NON-NUCLEOPHILIC HINERED ORGANIC BASE | 3M INNOVATIVE PROPERTIES COMPANY | 2001-06-19 | — | — | US | disclosed |
| US-6171522-B1 | Heterocyclic aromatic anion salts, and their uses as ionic conducting materials | Hydro-Qu{acute over (e)}bec (CA) | 2001-01-09 | — | — | US | disclosed |
| EP-0735992-B1 | METHOD OF CONVERTING HYDROXYL GROUPS INTO CORRESPONDING FLUORO COMPOUNDS | BAYER AG (DE) | 2001-01-03 | — | — | EP | disclosed |
| WO-2000031003-A1 | PROCESS FOR CONVERTING AN ALCOHOL TO THE CORRESPONDING FLUORIDE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2000-06-02 | — | — | WO | disclosed |
| EP-0735992-A1 | METHOD OF CONVERTING HYDROXYL GROUPS INTO CORRESPONDING FLUORO COMPOUNDS | BAYER AG (DE) | 1996-10-09 | — | — | EP | disclosed |
| WO-1996013474-A1 | METHOD OF CONVERTING HYDROXYL GROUPS INTO CORRESPONDING FLUORO COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-05-09 | — | — | WO | disclosed |
| EP-0339284-B1 | Fluorine-containing dielectric media and capacitors employing such media | ATOCHEM NORTH AMERICA (US) | 1994-06-29 | — | — | EP | disclosed |
| US-4899249-A | Fluorine-containing dielectric media and capacitors employing such media | PENNWALT CORPORATION (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0339284-A1 | Fluorine-containing dielectric media and capacitors employing such media | ATOCHEM NORTH AMERICA, INC. (a Pennsylvania corp.) (US) | 1989-11-02 | — | — | EP | disclosed |
| US-4168277-A | QUATERNIZATION OF TRIETHYLAMINE WITH AN ETHOXY SILANE, SALT FORMAT | BAYER AKTIENGESELLSCHAFT (DE) | 1979-09-18 | — | — | US | disclosed |
| US-3970586-A | Perfluoroalkane sulfonamido-alkane phosphonic and phosphonic acid derivatives | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-20 | — | — | US | disclosed |
| US-3970586-A | Perfluoroalkane sulfonamido-alkane phosphonic and phosphonic acid derivatives | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (31 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129472-A1 | METHOD OF MAKING A THERMOPLASTIC COMPOSITION CONTAINING AN ANTISTATIC AGENT | LBR, RPS4X, RER1 | CA2 251/4885CA1 113/4885MMP1 1501/4885 |
| US-20190218203-A1 | Neuroprotective Compounds and Use Thereof | NLN, GAP43, BDNF | CA2 3901/4885CA1 793/4885MMP1 2735/4885 |
| US-20110046406-A1 | PROCESS FOR THE PREPARATION OF (S)-2-AMINO-5-CYCLOPROPYL-4,4-DIFLUOROPENTANOIC ACID AND ALKYL ESTERS AND ACID SALTS THEREOF | DNPEP, CTRL, CTSS | CA2 398/4885CA1 118/4885MMP1 498/4885 |
| US-20140315971-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | KIF5B, KIF2C, KIF18B | CA2 2598/4885CA1 4331/4885MMP1 3040/4885 |
| US-20120028858-A1 | Process for the manufacture of functional PFPE derivative | PF4, PFAS, PFKP | CA2 1127/4885CA1 1650/4885MMP1 3312/4885 |
| US-20060009472-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | CA2 1526/4885CA1 3855/4885MMP1 3200/4885 |
| US-20040224933-A1 | Novel process and intermediates for preparing 17-halogenated 19-norsteroid compounds | CYP17A1, HSD17B7, HSD3B1 | CA2 4805/4885CA1 3084/4885MMP1 4443/4885 |
| US-10183913-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-20100034813-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | CA2 3748/4885CA1 3975/4885MMP1 4370/4885 |
| US-20170217902-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-20030022874-A1 | New 17-halogenated 19-nor steroids, preparation process and intermediates, use as medicaments and the pharmaceutical compositions containing them | HSD17B7, CYP11B1, CYP11B2 | CA2 4293/4885CA1 3926/4885MMP1 4380/4885 |
| US-11312688-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-20130116296-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-20200308119-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-20110064673-A1 | New L-Glutamic acid and L-Glutamine derivative (III), use thereof and method for obtaining them | GLUL, GATD3, QPCT | CA2 981/4885CA1 231/4885MMP1 4724/4885 |
| US-20140227191-A1 | L-GLUTAMIC ACID AND L-GLUTAMINE DERIVATIVE (III), USE THEREOF AND METHOD FOR OBTAINING THEM | GLUL, GATD3, QPCT | CA2 905/4885CA1 203/4885MMP1 4614/4885 |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | CA2 3748/4885CA1 3975/4885MMP1 4370/4885 |
| US-20090258016-A1 | Substituted imidazole derivatives | ABCG2, CYP2C19, AADAC | CA2 1526/4885CA1 3855/4885MMP1 3200/4885 |
| US-20080015377-A1 | METHODS OF MAKING AN ANTISTATIC AGENT | GPX1, GPX4, PRDX1 | CA2 14/4885CA1 12/4885MMP1 273/4885 |
| US-20160272619-A1 | Neuroprotective Compounds and Use Thereof | NLN, BDNF, CASP3 | CA2 4010/4885CA1 1358/4885MMP1 2318/4885 |
| US-20050228194-A1 | Methods of making an antistatic agent | MTX1, GPX4, CA2 | CA2 3/4885CA1 16/4885MMP1 522/4885 |
| US-10723703-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-20160176893-A1 | RAPAMYCIN ANALOGUES AND THEIR PHARMACEUTICAL USE | FKBP1A, FKBP1B, FKBP2 | CA2 3673/4885CA1 4726/4885MMP1 1564/4885 |
| US-20180273489-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-20080269526-A1 | METHODS OF MAKING AN ANTISTATIC AGENT | PGM2, CA6, NHERF1 | CA2 7/4885CA1 38/4885MMP1 886/4885 |
| US-20130017196-A1 | SUBSTITUTED IMIDAZOLE DERIVATIVES | ABCG2, CYP2C19, AADAC | CA2 1526/4885CA1 3855/4885MMP1 3200/4885 |
| US-20100278751-A1 | RADIOLABELED 2-AMINO-4-ALKYL-6-(HALOALKYL)PYRIDINE COMPOUNDS AND THEIR USE IN DIAGNOSTIC IMAGING | NOS2, NOS3, NOS1 | CA2 739/4885CA1 1937/4885MMP1 1706/4885 |
| US-20190084938-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-10087146-B2 | Pyrazole compound | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
| US-20140031406-A1 | PYRAZOLE COMPOUND | HTR2C, HTR3B, HTR3A | CA2 2270/4885CA1 1971/4885MMP1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.